COMMUNIQUÉS West-GlobeNewswire

Jounce Therapeutics Reports Third Quarter 2017 Financial Results

13/11/2017 - 12:30

- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to [...]

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017

13/11/2017 - 12:30

Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues in 2017 Guiding to $ [...]

Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs

13/11/2017 - 12:00

Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin [...]

Fennec Provides Business Update And Reports Third Quarter 2017 Results

13/11/2017 - 12:00

During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any [...]

Notice of Annual General Meeting

13/11/2017 - 11:37

Please see enclosed pdf.

Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation

13/11/2017 - 11:30

PLYMOUTH, Minn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL ), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that Anthem, Inc. now [...]

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

13/11/2017 - 11:00

ZUG, Switzerland and CAMBRIDGE, Mass. and TÜBINGEN, Germany, and BOSTON, Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a genome editing company focused on creating transformative gene-based [...]

Veritas and Cannevert Hires the Essèntium Group as Their Agent in Puerto Rico USA

13/11/2017 - 09:05

VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that the Company through its research arm, Cannevert [...]

NANOBIOTIX présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC

13/11/2017 - 08:02

Nanobiotix présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC NBTXR3 activé par la radiothérapie induit une réponse [...]

NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting

13/11/2017 - 08:02

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting NBTXR3 activated by radiotherapy induces a significant adaptive immune [...]

Xbrane Biopharma releases interim report for the period July to September 2017

13/11/2017 - 08:01

Press release 2017-11-13 Xbrane Biopharma ABs interim report for the period July - September 2017 is now available on the Company's website, www.xbrane.com . July to September Revenue SEK -47 thousand (-) EBITDA SEK -8, [...]

Novartis highlights its differentiated late stage pipeline at the R&D update and investor event

13/11/2017 - 07:01

RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a robust data package, even in [...]

argenx to Present at Upcoming Investor Conferences

13/11/2017 - 07:01

November 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Voyager Therapeutics to Host R&D Day on November 16, 2017

13/11/2017 - 00:00

CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, [...]

Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection

11/11/2017 - 23:45

– Clinical Data from Renal Cell Carcinoma Cohorts Presented in Oral Session at SITC 32 nd Annual Meeting – – Adenosine Pathway Gene Expression Associated with Response to Therapy and Resistance to Prior Anti PD-(L)-1 – [...]

Nextech Named Tampa Bay “Technology Company of the Year” for 2017 at the 14th Annual Tampa Bay Tech Awards

11/11/2017 - 23:28

TAMPA, Fla., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Nextech Systems , a leading provider of health care technology solutions for specialty physician practices, has been named the Technology Company of the Year for 2017 by [...]

Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

11/11/2017 - 14:30

DURHAM, N.C., Nov. 11, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the [...]

Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases

11/11/2017 - 14:01

Poor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make medicines available [...]

CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

11/11/2017 - 02:00

- CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models - - Expanding applicability of CRISPR-based CAR-T therapy [...]